Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study

INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qian, Jiang, Huiqin, Li, Hong, Xu, Ruihua, Shen, Lin, Yu, Yiyi, Wang, Yan, Cui, Yuehong, Li, Wei, Yu, Shan, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226611/
https://www.ncbi.nlm.nih.gov/pubmed/27409420
http://dx.doi.org/10.18632/oncotarget.10456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226611/
https://www.ncbi.nlm.nih.gov/pubmed/27409420
http://dx.doi.org/10.18632/oncotarget.10456

Ejemplares similares